Absolute required reading for anyone who designs protocols or is engaged in recruiting patients into clinical trials: Susan Guber writes eloquently about her experiences as a participant in cancer clinical trials.
New York Times Well Blog: The Trials of Cancer Trials
|Today's #FDAFridayPhoto features Harvey |
Wiley, leader of the famed FDA "Poison Squad".
The popular press in India continues to be disingenuous and exploitative in its coverage of clinical trial deaths in that country. (My previous thoughts on that are here.) Kiran Mazumdar-Shaw, an industry leader, has put together an intelligent and articulate antidote.
The Economic Times: Need a rational view on clinical trials
Rahlen Gossen exhibits mastery of the understatement: “Though the Facebook Insights dashboard is a great place to start, it has a few significant disadvantages.” She also provides a good overview of the most common pitfalls you’ll encounter when you try to get good metrics out of your Facebook campaign.
Rebar Interactive Blog: Metrics Gone Wrong: Facebook “Likes” in Clinical Research
I have not had a chance to watch it yet, but I’m excited to see that theHeart.org has just posted a 7-part video editorial series by Yale’s Harlan Krumholz and
Duke Stanford’s Bob Harrington on “a frank discussion on the controversies in the world of clinical trials”.
theHeart.org: Rethinking clinical trials and research in cardiology